220 related articles for article (PubMed ID: 33713599)
1. Structural mechanism underlying ligand binding and activation of PPARγ.
Shang J; Kojetin DJ
Structure; 2021 Sep; 29(9):940-950.e4. PubMed ID: 33713599
[TBL] [Abstract][Full Text] [Related]
2. Cooperative cobinding of synthetic and natural ligands to the nuclear receptor PPARγ.
Shang J; Brust R; Mosure SA; Bass J; Munoz-Tello P; Lin H; Hughes TS; Tang M; Ge Q; Kamenekca TM; Kojetin DJ
Elife; 2018 Dec; 7():. PubMed ID: 30575522
[TBL] [Abstract][Full Text] [Related]
3. Defining a conformational ensemble that directs activation of PPARγ.
Chrisman IM; Nemetchek MD; de Vera IMS; Shang J; Heidari Z; Long Y; Reyes-Caballero H; Galindo-Murillo R; Cheatham TE; Blayo AL; Shin Y; Fuhrmann J; Griffin PR; Kamenecka TM; Kojetin DJ; Hughes TS
Nat Commun; 2018 May; 9(1):1794. PubMed ID: 29728618
[TBL] [Abstract][Full Text] [Related]
4. A molecular switch regulating transcriptional repression and activation of PPARγ.
Shang J; Mosure SA; Zheng J; Brust R; Bass J; Nichols A; Solt LA; Griffin PR; Kojetin DJ
Nat Commun; 2020 Feb; 11(1):956. PubMed ID: 32075969
[TBL] [Abstract][Full Text] [Related]
5. Ligand and receptor dynamics contribute to the mechanism of graded PPARγ agonism.
Hughes TS; Chalmers MJ; Novick S; Kuruvilla DS; Chang MR; Kamenecka TM; Rance M; Johnson BA; Burris TP; Griffin PR; Kojetin DJ
Structure; 2012 Jan; 20(1):139-50. PubMed ID: 22244763
[TBL] [Abstract][Full Text] [Related]
6. Ligand entry pathways in the ligand binding domain of PPARγ receptor.
Aci-Sèche S; Genest M; Garnier N
FEBS Lett; 2011 Aug; 585(16):2599-603. PubMed ID: 21782815
[TBL] [Abstract][Full Text] [Related]
7. Agonism activities of lyso-phosphatidylcholines (LPC) Ligands binding to peroxisome proliferator-activated receptor gamma (PPARγ).
Wang J; Wang B; Zhang Y
J Biomol Struct Dyn; 2020 Feb; 38(2):398-409. PubMed ID: 31025599
[TBL] [Abstract][Full Text] [Related]
8. Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding.
Batista FA; Trivella DB; Bernardes A; Gratieri J; Oliveira PS; Figueira AC; Webb P; Polikarpov I
PLoS One; 2012; 7(5):e33643. PubMed ID: 22606221
[TBL] [Abstract][Full Text] [Related]
9. Modification of the Orthosteric PPARγ Covalent Antagonist Scaffold Yields an Improved Dual-Site Allosteric Inhibitor.
Brust R; Lin H; Fuhrmann J; Asteian A; Kamenecka TM; Kojetin DJ
ACS Chem Biol; 2017 Apr; 12(4):969-978. PubMed ID: 28165718
[TBL] [Abstract][Full Text] [Related]
10. Quantitative structural assessment of graded receptor agonism.
Shang J; Brust R; Griffin PR; Kamenecka TM; Kojetin DJ
Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22179-22188. PubMed ID: 31611383
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor gamma (PPARγ) has multiple binding points that accommodate ligands in various conformations: Structurally similar PPARγ partial agonists bind to PPARγ LBD in different conformations.
Ohashi M; Gamo K; Oyama T; Miyachi H
Bioorg Med Chem Lett; 2015 Jul; 25(14):2758-62. PubMed ID: 26025876
[TBL] [Abstract][Full Text] [Related]
12. Ligand-escape pathways from the ligand-binding domain of PPARgamma receptor as probed by molecular dynamics simulations.
Genest D; Garnier N; Arrault A; Marot C; Morin-Allory L; Genest M
Eur Biophys J; 2008 Apr; 37(4):369-79. PubMed ID: 17929009
[TBL] [Abstract][Full Text] [Related]
13. Molecular Modeling of Allosteric Site of Isoform-Specific Inhibition of the Peroxisome Proliferator-Activated Receptor PPARγ.
Almahmoud S; Zhong HA
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358965
[TBL] [Abstract][Full Text] [Related]
14. Insights into Dynamic Mechanism of Ligand Binding to Peroxisome Proliferator-Activated Receptor γ toward Potential Pharmacological Applications.
Miyamae Y
Biol Pharm Bull; 2021; 44(9):1185-1195. PubMed ID: 34471046
[TBL] [Abstract][Full Text] [Related]
15. Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping.
Sheu SH; Kaya T; Waxman DJ; Vajda S
Biochemistry; 2005 Feb; 44(4):1193-209. PubMed ID: 15667213
[TBL] [Abstract][Full Text] [Related]
16. Insights into the mechanism of partial agonism: crystal structures of the peroxisome proliferator-activated receptor gamma ligand-binding domain in the complex with two enantiomeric ligands.
Pochetti G; Godio C; Mitro N; Caruso D; Galmozzi A; Scurati S; Loiodice F; Fracchiolla G; Tortorella P; Laghezza A; Lavecchia A; Novellino E; Mazza F; Crestani M
J Biol Chem; 2007 Jun; 282(23):17314-24. PubMed ID: 17403688
[TBL] [Abstract][Full Text] [Related]
17. Derivation of a retinoid X receptor scaffold from peroxisome proliferator-activated receptor gamma ligand 1-Di(1H-indol-3-yl)methyl-4-trifluoromethylbenzene.
Dawson MI; Ye M; Cao X; Farhana L; Hu QY; Zhao Y; Xu LP; Kiselyuk A; Correa RG; Yang L; Hou T; Reed JC; Itkin-Ansari P; Levine F; Sanner MF; Fontana JA; Zhang XK
ChemMedChem; 2009 Jul; 4(7):1106-19. PubMed ID: 19378296
[TBL] [Abstract][Full Text] [Related]
18. Multi-conformation dynamic pharmacophore modeling of the peroxisome proliferator-activated receptor γ for the discovery of novel agonists.
Sohn YS; Park C; Lee Y; Kim S; Thangapandian S; Kim Y; Kim HH; Suh JK; Lee KW
J Mol Graph Model; 2013 Nov; 46():1-9. PubMed ID: 24104184
[TBL] [Abstract][Full Text] [Related]
19. Different binding and recognition modes of GL479, a dual agonist of Peroxisome Proliferator-Activated Receptor α/γ.
dos Santos JC; Bernardes A; Giampietro L; Ammazzalorso A; De Filippis B; Amoroso R; Polikarpov I
J Struct Biol; 2015 Sep; 191(3):332-40. PubMed ID: 26185032
[TBL] [Abstract][Full Text] [Related]
20. Structural basis for PPARγ transactivation by endocrine-disrupting organotin compounds.
Harada S; Hiromori Y; Nakamura S; Kawahara K; Fukakusa S; Maruno T; Noda M; Uchiyama S; Fukui K; Nishikawa J; Nagase H; Kobayashi Y; Yoshida T; Ohkubo T; Nakanishi T
Sci Rep; 2015 Feb; 5():8520. PubMed ID: 25687586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
